Geometric mean titre ratios (Day22:Day1) in all subjects in the Phase II/III trial

<p><b>Copyright information:</b></p><p>Taken from "Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects"</p><p>http://www.immunityageing.com/content/5/1/2</p><p>Immunity & ageing : I & A 2008;5():2-2.</p><p>Published online 20 Feb 2008</p><p>PMCID:PMC2291031.</p><p></p

Pre-vaccination (Day 1) and post-vaccination (Day 22) geometric mean titre against a) A/H1N1, b) A/H3N2 and c) B viral strains in subjects without pre-vaccination immunoprotection

<p><b>Copyright information:</b></p><p>Taken from "Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects"</p><p>http://www.immunityageing.com/content/5/1/2</p><p>Immunity & ageing : I & A 2008;5():2-2.</p><p>Published online 20 Feb 2008</p><p>PMCID:PMC2291031.</p><p></p

Number and percentages of participants with solicited adverse events after any vaccination, and unsolicited and serious adverse events throughout the study (safety set).

<p>Number and percentages of participants with solicited adverse events after any vaccination, and unsolicited and serious adverse events throughout the study (safety set).</p

Participant flow diagram.

<p>Group A1, participants receiving PCECV according to the 4-site/1-week ID regimen; Group A2, participants receiving PCECV according to the 4-site/1-week ID regimen and HRIG at first visit; Group B1, participants receiving PCECV according to the 2-site/TRC regimen; Group B2, participants receiving PCECV according to the 2-site/TRC regimen and HRIG at first visit; PCECV, purified chick embryo cell culture vaccine; ID, intradermal; HRIG, human rabies immunoglobulin; TRC, Thai Red Cross; n, number of participants in each age stratum; N, number of participants in each group; PPS, per-protocol set. * One 11-year-old participant was erroneously randomized in Group B2. ** Not due to an adverse event.</p

Study design.

<p>Group A1, participants receiving PCECV according to the 4-site/1-week ID regimen; Group A2, participants receiving PCECV according to the 4-site/1-week ID regimen and HRIG at first visit; Group B1, participants receiving PCECV according to the 2-site/TRC ID regimen; Group B2, participants receiving PCECV according to the 2-site/TRC ID regimen and HRIG at first visit; PCECV, purified chick embryo cell culture vaccine; ID, intradermal; HRIG, human rabies immunoglobulin; TRC, Thai Red Cross; D, day; BD, blood draw. Administration schemes represent injection sites. The syringe symbolizes 1 injection of 0.1 mL of PCECV vaccine.</p

Demographics characteristics of participants at enrolment.

<p>Demographics characteristics of participants at enrolment.</p